Transdermal Pharmaceutical Packaging Market

The transdermal pharma packaging market is projected to grow from USD 4.05 billion in 2025 to USD 8.13 billion by 2030, at a CAGR of 15.0%. The increasing demand for painless and minimally invasive transdermal delivery technologies, such as microneedles and electroporation, is the major factor driving the market. Innovations in transdermal delivery systems are significantly contributing to the pharmaceutical packaging market. Additionally, the market for transdermal pharma packaging is boosted by the rising prevalence of chronic diseases and the growing demand for patient-friendly medication delivery systems.

The key players in this market are 3M Company (US), Hisamitsu Pharmaceutical (Japan), Novartis (Switzerland), Teva Pharmaceutical Industries (Israel), Johnson & Johnson (US), Bayer (Germany), GlaxoSmithKline (UK), LTS Lohmann Therapie-Systeme (Germany), Noven Pharmaceuticals (US), and Nitto Denko (Japan), among other notable contributors expanding and enriching the market with their innovative packaging solutions for workflow efficiency and healthcare quality. The key growth strategies adopted by key players include collaborations, joint ventures, product launches & development, expansions, and mergers & acquisitions.

To know about the assumptions considered for the study download the pdf brochure

In March 2024, 3M Company collaborated with Pfizer to develop advanced transdermal drug delivery systems, combining 3M’s expertise in adhesive technologies and patch design with Pfizer’s therapeutic pipeline. The company has established itself as a leader in transdermal pharmaceutical packaging through its development of next-generation patch platforms, which enhance drug delivery efficiency and patient adherence while maintaining controlled drug release, thereby meeting the increased demand for non-invasive drug delivery methods.

The July 2025 announcement by Hisamitsu Pharmaceutical regarding its joint development agreement with TOYO Pharmaceutical for a project to distribute a drug for treating postherpetic neuralgia reinforces the company’s leadership in transdermal therapeutics. Through this collaboration, Hisamitsu demonstrates its continued commitment to advancing its transdermal drug delivery systems by developing innovative pain-management therapies. Additionally, such strategic partnerships support the commercialization of its advanced patch-based treatments across the broader pharmaceutical packaging and drug delivery market.

3M Company plays a crucial role in the transdermal pharmaceutical packaging and drug delivery industry, leveraging its expertise in adhesive technologies, specialty films, and drug-in-adhesive patch systems. The company provides integrated solutions for transdermal patches, including backing films, liners, and pressure-sensitive adhesives, which create controlled drug release systems that improve skin drug absorption. 3M advances next-generation transdermal systems through its commitment to research and development and material science, and its partnership with pharmaceutical companies, which helps create non-invasive drug delivery methods that increase patient adherence.

Hisamitsu Pharmaceutical operates as the top company that provides transdermal pharmaceutical packaging and drug delivery solutions while developing and marketing transdermal patch-based treatment methods. The company utilizes its specialized knowledge of drug-in-adhesive technologies, patch formulation, and large-scale production methods to produce stable and controlled drug delivery systems that treat pain and anti-inflammatory conditions. Hisamitsu establishes itself as a vital force in promoting non-invasive transdermal delivery system usage through its worldwide operations and ongoing research and development activities, which create packaging solutions that maintain product stability, adhesion quality, and patient usability.

Market Ranking

The key players in the transdermal pharma packaging market have gained recognition for their comprehensive product offerings and continuous technological innovations. Some major players in the transdermal pharma packaging market include 3M Company (US), Hisamitsu Pharmaceutical (Japan), Novartis (Switzerland), Teva Pharmaceutical Industries (Israel), Johnson & Johnson (US), Bayer (Germany), GlaxoSmithKline (UK), LTS Lohmann Therapie-Systeme (Germany), Noven Pharmaceuticals (US), and Nitto Denko (Japan). 3M and Hisamitsu have gained recognition for offering sophisticated packaging solutions, including specialized materials and designs for transdermal applications suitable for pharmaceutical manufacturing and clinical use. Novartis and Teva Pharmaceutical maintain market leadership through their integrated pharmaceutical packaging solutions, enabling reliable product protection, precise containment, and prompt manufacturing and clinical decision-making in both routine and specialized pharmaceutical production settings. Other notable contributors are expanding and enriching the market with their innovative packaging equipment for workflow efficiency and healthcare quality. The key players have contributed significantly, increasing the reach of transdermal pharmaceutical packaging solutions in the global market.

Related Reports:

Transdermal Pharmaceutical Packaging Market by Type (Patches, Gels), Material (Plastic, Glass, Metal), Application (Chronic Disease Management, Pain Management, Hormone Replacement Therapy), and Region – Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]